The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Reducing the burden of PNH with next-generation complement inhibitors
Eleni Gavriilaki, MD, PhD, Aristotle University of Thessaloniki, Thessaloniki, Greece, discusses the burden of paroxysmal nocturnal hemoglobinuria (PNH). While complement inhibitors have revolutionized PNH treatment, unmet needs remain for patients who lack access to these drugs or do not respond well to first-generation agents. Dr Gavriilaki anticipates that next-generation agents will benefit these patients. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
